These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35066461)

  • 1. State-level regulations and opioid-related health outcomes.
    Jackson JR; Harle CA; Silverman R; Simon K; Menachemi N
    Drug Alcohol Depend; 2022 Mar; 232():109294. PubMed ID: 35066461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing variability in state-level regulations governing opioid treatment programs.
    Jackson JR; Harle CA; Silverman RD; Simon K; Menachemi N
    J Subst Abuse Treat; 2020 Aug; 115():108008. PubMed ID: 32600617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations.
    D'Aunno T; Pollack HA; Jiang L; Metsch LR; Friedmann PD
    Health Serv Res; 2014 Feb; 49(1):230-48. PubMed ID: 23855724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.
    Conway A; Krawczyk N; McGaffey F; Doyle S; Baaklini V; Marshall AD; Treloar C; Davis CS; Colledge-Frisby S; Grebely J; Cerdá M
    Int J Drug Policy; 2023 Sep; 119():104141. PubMed ID: 37540917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Rural Opioid Treatment Program (OTP) Facilities Associated with Lower Deaths?
    Meadowcroft D; Whitacre B
    Subst Use Misuse; 2020; 55(5):828-838. PubMed ID: 31856628
    [No Abstract]   [Full Text] [Related]  

  • 8. The associations of medical marijuana policies with opioid-related health care utilization.
    Jayawardhana J; Fernandez JM
    Health Serv Res; 2021 Apr; 56(2):299-309. PubMed ID: 33501701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
    Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
    Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new services that opioid treatment programs have adopted in response to COVID-19.
    Cantor J; Laurito A
    J Subst Abuse Treat; 2021 Nov; 130():108393. PubMed ID: 34118694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey.
    Bandara S; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Krawczyk N
    BMC Health Serv Res; 2022 Mar; 22(1):418. PubMed ID: 35354460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.
    Abraham AJ; Yarbrough CR; Harris SJ; Adams GB; Andrews CM
    Psychiatr Serv; 2021 Feb; 72(2):148-155. PubMed ID: 33267651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status.
    Pro G; Tompkins DA; Azari S; Zaller N
    Drug Alcohol Depend; 2021 Nov; 228():109092. PubMed ID: 34571287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19.
    Joseph G; Torres-Lockhart K; Stein MR; Mund PA; Nahvi S
    J Subst Abuse Treat; 2021 Mar; 122():108219. PubMed ID: 33353790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    J Subst Abuse Treat; 2016 Apr; 63():46-53. PubMed ID: 26810130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of age and opioid agonist treatment on substance use treatment completion in the United States.
    van den Berk Clark C; Pickard JG; Drallmeier T
    Aging Ment Health; 2022 Jun; 26(6):1295-1302. PubMed ID: 33999741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public interest in medication-assisted treatment for opioid used disorder in the United States.
    Niforatos JD; Zheutlin AR; Pescatore RM; Raja AS
    Am J Emerg Med; 2019 Oct; 37(10):1983-1985. PubMed ID: 31056384
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.